WallStreetZenWallStreetZen

NASDAQ: COCP
Cocrystal Pharma Inc Stock

$3.15+0.10 (+3.28%)
Updated Feb 3, 2023
COCP Price
$3.15
Fair Value Price
$8.31
Market Cap
$25.65M
52 Week Low
$1.74
52 Week High
$7.56
P/E
-0.68x
P/B
0.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.02M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$19M
Beta
0.1
Next Earnings
Mar 21, 2023
Ex-Dividend
N/A
Next Dividend
N/A

COCP Overview

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how COCP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

COCP ($3.15) is undervalued by 62.12% relative to our estimate of its Fair Value price of $8.31 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
COCP ($3.15) is significantly undervalued by 62.12% relative to our estimate of its Fair Value price of $8.31 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
COCP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COCP due diligence checks available for Premium users.

Be the first to know about important COCP news, forecast changes, insider trades & much more!

COCP News

Valuation

COCP fair value

Fair Value of COCP stock based on Discounted Cash Flow (DCF)
Price
$3.15
Fair Value
$8.31
Undervalued by
62.12%
COCP ($3.15) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COCP ($3.15) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COCP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

COCP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.68x
Industry
10.7x
Market
15.09x

COCP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
5.11x
COCP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

COCP's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.7M
Profit Margin
0%
COCP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$45.6M
Liabilities
$1.7M
Debt to equity
0.04
COCP's short-term assets ($44.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COCP's short-term assets ($44.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COCP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COCP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.9M
Investing
-$62.0k
Financing
-$7.0k
COCP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

COCP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
COCP$25.65M+3.28%-0.68x0.58x
CMMB$25.59M+1.37%-1.05x0.57x
VCNX$25.20M0.00%-1.16x3.99x
RUBY$25.12M-5.44%-0.12x0.69x
CMRA$26.20M-1.49%N/A-7.64x

Cocrystal Pharma Stock FAQ

What is Cocrystal Pharma's quote symbol?

NASDAQ: COCP) Cocrystal Pharma trades on the NASDAQ under the ticker symbol COCP. Cocrystal Pharma stock quotes can also be displayed as NASDAQ: COCP.

If you're new to stock investing, here's how to buy Cocrystal Pharma stock.

What is the 52 week high and low for Cocrystal Pharma (NASDAQ: COCP)?

(NASDAQ: COCP) Cocrystal Pharma's 52-week high was $7.56, and its 52-week low was $1.74. It is currently -58.33% from its 52-week high and 81.03% from its 52-week low.

How much is Cocrystal Pharma stock worth today?

(NASDAQ: COCP) Cocrystal Pharma currently has 8,143,000 outstanding shares. With Cocrystal Pharma stock trading at $3.15 per share, the total value of Cocrystal Pharma stock (market capitalization) is $25.65M.

Cocrystal Pharma stock was originally listed at a price of $57.00 in Mar 12, 2018. If you had invested in Cocrystal Pharma stock at $57.00, your return over the last 4 years would have been -94.47%, for an annualized return of -51.51% (not including any dividends or dividend reinvestments).

How much is Cocrystal Pharma's stock price per share?

(NASDAQ: COCP) Cocrystal Pharma stock price per share is $3.15 today (as of Feb 3, 2023).

What is Cocrystal Pharma's Market Cap?

(NASDAQ: COCP) Cocrystal Pharma's market cap is $25.65M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cocrystal Pharma's market cap is calculated by multiplying COCP's current stock price of $3.15 by COCP's total outstanding shares of 8,143,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.